FDA Approves Boxed Warning for Immune Effector Cell-Associated Enterocolitis Following Treatment With Ciltacabtagene Autoleucel.

The article focuses on the U.S. Food and Drug Administration’s (FDA) updated safety information for ciltacabtagene autoleucel (Carvykti®), a treatment for relapsed and lenalidomide-refractory multiple myeloma. The FDA has added warnings about immune effector cell-associated enterocolitis (IEC-EC), a serious condition characterized by severe diarrhea, abdominal pain, weight loss, and potentially fatal complications such as gut perforation and sepsis, occurring weeks to months after treatment. Despite these risks, the FDA concluded that the overall survival benefits of ciltacabtagene autoleucel outweigh its potential harms. The updates include changes to the prescribing information’s Boxed Warning, Warnings and Precautions, and Adverse Reactions sections, and healthcare providers are encouraged to report adverse events through the FDA’s MedWatch program.